학술논문
Incidence of adverse events prompting switching between biologics among adults with asthma: A retrospective cohort study.
Document Type
Article
Author
Source
Subject
*WHEEZE
*NASAL polyps
*ASTHMA
*BIOLOGICALS
*
*
*
Language
ISSN
0105-4538
Abstract
Six monoclonal antibodies ("biologics") are currently approved for the treatment of asthma in the US.[1] While these biologics demonstrated favorable safety profiles in pre-approval trials, these trials had relatively short follow-up periods. Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study. [Extracted from the article]